Thymidylate synthase inhibitory drugs induce p53-dependent pathways differently
Eszter Holub, Milda Blanka Szajkó, Anna Felföldi, Beáta G Vértessy, Angéla Békési · 2026
Read Thymidylate synthase inhibitory drugs induce p53-dependent pathways differently by Eszter Holub, Milda Blanka Szajkó, Anna Felföldi, Beáta G Vértessy, Angéla Békési (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0332491.txt.
Description
Eszter Holub and four colleagues compare two chemotherapy drugs in a 2026 cell study. Both drugs block thymidylate synthase, an enzyme cancer cells need to copy DNA. Blocking it corrupts the DNA building blocks and triggers cell death. The drugs studied are a fluorouridine compound and raltitrexed. The team used human colon cancer cells, including lines with damaged DNA repair systems.
Both drugs switched on DNA damage responses, as expected. Yet their wider effects on gene activity differed sharply. The fluorouridine drug strongly activated genes tied to p53, the cell's damage guardian, in every cell line. The other drug did not lean on that pathway in the same way. Protein tests confirmed the difference. Two drugs with the same main target can thus kill cells through partly different routes, which matters for choosing treatments and combinations.
Catalog record
| CREATOR | Eszter Holub, Milda Blanka Szajkó, Anna Felföldi, Beáta G Vértessy, Angéla Békési |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 101458 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |